Coya Therapeutics, Inc.
Coya Therapeutics, Inc. (COYA): 8 pipeline candidates · 1 upcoming catalyst · ~25 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
24.9 months
D/E 0.09 · 0% dilution
Lead: Phase 2
8 candidates
1 upcoming, next in ~286d
N/A
A transparent, data-derived signal for Coya Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$118.0M
Cash
$50.7M
Quarterly Burn
$6.2M
Runway
24.9 mo
Revenue
$251K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
54
Total value held
$21.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,689,826 | $6.7M |
| alyeska investment group, l.p. | 800,000 | $3.2M |
| prosight management, lp | 420,360 | $1.7M |
| private management group inc | 369,096 | $1.5M |
| geode capital management, llc | 233,402 | $920K |
| marshall wace, llp | 225,792 | $890K |
| vanguard fiduciary trust co | 139,886 | $551K |
| renaissance technologies llc | 103,964 | $410K |
| prelude capital management, llc | 101,330 | $399K |
| jbf capital, inc. | 100,006 | $394K |
Showing top 10 of 54 institutional holders of Coya Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Coya Therapeutics, Inc.'s pipeline?
Coya Therapeutics, Inc. (COYA) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Coya Therapeutics, Inc.'s lead drug candidate?
Coya Therapeutics, Inc.'s most advanced tracked candidate is Arm 1 (Phase 2) for Kidney Transplantation.
What is Coya Therapeutics, Inc.'s next catalyst?
Coya Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: alstars" — expected March 31, 2027.
What is Coya Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Coya Therapeutics, Inc. has approximately 24.9 months of cash runway.
What is Coya Therapeutics, Inc.'s market capitalization?
Coya Therapeutics, Inc.'s market capitalization is approximately $118.0M.
Get the full picture on Coya Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.